Breast Cancer Research and Treatment

, Volume 141, Issue 3, pp 325–330 | Cite as

Pharmacological treatment of depression in women with breast cancer: a systematic review

  • Lærke Toftegård Andersen
  • Melissa Voigt Hansen
  • Jacob Rosenberg
  • Ismail Gögenur
Review

Abstract

The objective of this study is to review the literature on pharmacological treatment of depression in women with breast cancer. According to the PRISMA guidelines, we conducted a systematic review of randomized, controlled clinical trials and open label prospective studies on antidepressants effects on depression in women with breast cancer up to January 14, 2013. In this analysis, a total of 213 studies were identified, and six studies met the inclusion criteria. Of the six studies, three were placebo-controlled randomized controlled clinical trials with fluoxetine, a selective serotonin reuptake inhibitor; and Mianserin—a noradrenergic and specific serotonergic antidepressant. Both studies found that fluoxetine and mianserin significantly improved depressive symptoms and quality of life (QOL) compared with placebo. Conversely, desipramine, a tricyclic antidepressant, and the SSRI, paroxetine, showed no significant effects on depression compared with placebo. A double-blind, parallel group study comparing a tricyclic antidepressant, amitriptyline, and paroxetine showed a significant and comparable improvement in depression and QOL. Two open label, prospective studies found that escitalopram and the norepinephrine reuptake inhibitor, reboxetine, significantly improved depression and QOL compared with baseline values. In conclusion, depression is a clinical problem in patients with breast cancer. Pharmacological treatment with antidepressants may improve depression and QOL. However, the evidence is limited, and the studies are too heterogeneous to recommend one regimen or drug over another. Further antidepressant studies are needed to guide depression treatment in patients with breast cancer.

Keywords

Breast cancer Oncology Antidepressants Depression Depressive symptoms Pharmacological treatment 

Notes

Acknowledgments

The Lundbeck foundation supported the main author Lærke Toftegård Andersen with a scholarship.

Conflict of interest

The authors declare that they have no commercial or other associations that might pose a conflict of interest in connection with this article.

References

  1. 1.
    Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A (2005) Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ 330:702PubMedCrossRefGoogle Scholar
  2. 2.
    Suppli NP, Deltour I, Damkjaer LH, Christensen J, Jensen AB, Kroman NT, Johansen C, Dalton SO (2011) Factors associated with the prescription of antidepressive medication to breast cancer patients. Acta Oncol 50:243–251. doi:10.3109/0284186X.2010.531049 PubMedCrossRefGoogle Scholar
  3. 3.
    Azzone V, Frank RG, Pakes JR, Earle CC, Hassett MJ (2009) Behavioral health services for women who have breast cancer. J Clin Oncol 27:706–712. doi:10.1200/JCO.2008.16.3006 PubMedCrossRefGoogle Scholar
  4. 4.
    Ashbury FD, Madlensky L, Raich P, Thompson M, Whitney G, Hotz K, Kralj B, Edell WS (2003) Antidepressant prescribing in community cancer care. Support Care Cancer 11:278–285PubMedGoogle Scholar
  5. 5.
    Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160–174. doi:10.1016/S1470-2045(11)70002-X PubMedCrossRefGoogle Scholar
  6. 6.
    Dalton SO, Laursen TM, Ross L, Mortensen PB, Johansen C (2009) Risk for hospitalization with depression after a cancer diagnosis: a nationwide, population-based study of cancer patients in Denmark from 1973 to 2003. J Clin Oncol 27:1440–1445. doi:10.1200/JCO.2008.20.5526 PubMedCrossRefGoogle Scholar
  7. 7.
    Fallowfield L, Ratcliffe D, Jenkins V, Saul J (2001) Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer 84:1011–1015PubMedCrossRefGoogle Scholar
  8. 8.
    Dantzer R (2009) Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 29:247–264. doi:10.1016/j.iac.2009.02.002 PubMedCrossRefGoogle Scholar
  9. 9.
    Fann JR, Thomas-Rich AM, Keaton WJ, Cowley D, Pepping M, McGregor BA, Gralow J (2008) Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry 30:112–126. doi:10.1016/j.genhosppsych.2007.10.008 PubMedCrossRefGoogle Scholar
  10. 10.
    Holland JC, Romano SJ, Heiligenstein JH, Tepner RG, Wilson MG (1998) A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 7:291–300PubMedCrossRefGoogle Scholar
  11. 11.
    Ng CG, Boks MPM, Zainal NZ, De Wit NJ (2011) The prevalence and pharmacotherapy of depression in cancer patients. J Affect Disord 131:1–7. doi:10.1016/j.jad.2010.07.034 PubMedCrossRefGoogle Scholar
  12. 12.
    Bray F, Ren JS, Masuyer A, Ferlay J (2013) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132:1133–1145. doi:10.1002/ijc.27711 PubMedCrossRefGoogle Scholar
  13. 13.
    Rosso S, Gondos A, Zanetti R, Bray F, Zakelj M, Zagar T, Smailyte G, Ponti A, Brewster DH (2010) Up-to-date estimates of breast cancer survival for the years 2000–2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer 46:3351–3357. doi:10.1016/j.ejca.2010.09.019 PubMedCrossRefGoogle Scholar
  14. 14.
    Autier P, Boniol M, La Vecchia C, LaVecchia C, Vatten L, Gavin A, Héry C, Heanue M (2010) Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ 341:c3620. doi:10.1136/bmj.c3620 PubMedCrossRefGoogle Scholar
  15. 15.
    Rowland JH, Hewitt M, Ganz PA (2006) Cancer survivorship: a new challenge in delivering quality cancer care. J Clin Oncol 24:5101–5104PubMedCrossRefGoogle Scholar
  16. 16.
    Spiegel D, Giese-Davis J (2003) Depression and cancer: mechanisms and disease progression. Biol Psychiatry 54:269–282PubMedCrossRefGoogle Scholar
  17. 17.
    Satin JR, Linden W, Phillips MJ (2009) Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 115:5349–5361. doi:10.1002/cncr.24561 PubMedCrossRefGoogle Scholar
  18. 18.
    Hjerl K, Andersen EW, Keiding N, Mouridsen HT, Mortensen PB, Jørgensen T (2003) Depression as a prognostic factor for breast cancer mortality. Psychosomatics 44:24–30PubMedCrossRefGoogle Scholar
  19. 19.
    DiMatteo MR, Lepper HS, Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101–2107PubMedCrossRefGoogle Scholar
  20. 20.
    Somerset W, Stout SC, Miller AH, Musselman D (2004) Breast cancer and depression. Oncology 18:1021–1034PubMedGoogle Scholar
  21. 21.
    Meade E, Dowling M (2012) Early breast cancer: diagnosis, treatment and survivorship. Br J Nurs 21:S4–8, S10Google Scholar
  22. 22.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. doi:10.1371/journal.pmed.1000100 Google Scholar
  23. 23.
    Navari RM, Brenner MC, Wilson MN (2008) Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat 112:197–201PubMedCrossRefGoogle Scholar
  24. 24.
    Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB (2006) A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. J Clin Psychiatry 67:288–296PubMedCrossRefGoogle Scholar
  25. 25.
    Van Heeringen K, Zivkov M (1996) Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry 169:440–443PubMedCrossRefGoogle Scholar
  26. 26.
    Pezzella G, Moslinger-Gehmayr R, Contu A (2001) Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 70:1–10PubMedCrossRefGoogle Scholar
  27. 27.
    Park HY, Lee B-J, Kim J-H, Bae J-N, Hahm B-J (2012) Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial. Prog Neuropsychopharmacol Biol Psychiatry 36:318–323. doi:0.1016/j.pnpbp.2011.11.010 PubMedCrossRefGoogle Scholar
  28. 28.
    Grassi L, Biancosino B, Marmai L, Righi R (2004) Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. J Clin Psychiatry 65:515–520PubMedCrossRefGoogle Scholar
  29. 29.
    Papakostas GI (2008) Tolerability of modern antidepressants. J Clin Psychiatry 69:8–13PubMedCrossRefGoogle Scholar
  30. 30.
    Baldwin DS, Montgomery SA, Nil R, Lader M (2007) Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10:73–84PubMedCrossRefGoogle Scholar
  31. 31.
    Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA (2011) Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. doi:10.1002/14651858.CD006528 PubMedGoogle Scholar
  32. 32.
    Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062–1075PubMedCrossRefGoogle Scholar
  33. 33.
    Breitbart W (2011) Do antidepressants reduce the effectiveness of tamoxifen? Psychooncology 20:1–4. doi:10.1002/pon.1872 PubMedCrossRefGoogle Scholar
  34. 34.
    Desmarais JE, Looper KJ (2009) Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 70:1688–1697. doi:10.4088/JCP.08r04856blu PubMedCrossRefGoogle Scholar
  35. 35.
    Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693. doi:10.1136/bmj.c693 PubMedCrossRefGoogle Scholar
  36. 36.
    Siegelmann-Danieli N, Kurnik D, Lomnicky Y, Vesterman-Landes J, Katzir I, Biallik M, Loebstein R (2011) Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 125:505–510. doi:10.1007/s10549-010-1008-7 PubMedCrossRefGoogle Scholar
  37. 37.
    Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M (2008) Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 165:1251–1255. doi:10.1176/appi.ajp.2008.08040482 PubMedCrossRefGoogle Scholar
  38. 38.
    Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Vohra S, Klassen TP, Baker G (2006) Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 332:385–393PubMedCrossRefGoogle Scholar
  39. 39.
    Hickie IB, Rogers NL (2011) Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 378:621–631. doi:10.1016/S0140-6736(11)60095-0 PubMedCrossRefGoogle Scholar
  40. 40.
    De Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ (2010) Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 9:628–642. doi:10.1038/nrd3140 PubMedCrossRefGoogle Scholar
  41. 41.
    Acil M, Basgul E, Celiker V, Karagöz AH, Demir B, Aypar U (2004) Perioperative effects of melatonin and midazolam premedication on sedation, orientation, anxiety scores and psychomotor performance. Eur J Anaesthesiol 21:553–557PubMedGoogle Scholar
  42. 42.
    Hofmann SG, Sawyer AT, Witt AA, Oh D (2010) The effect of mindfulness-based therapy on anxiety and depression: a meta-analytic review. J Consult Clin Psychol 78:169–183. doi:10.1037/a0018555 PubMedCrossRefGoogle Scholar
  43. 43.
    Zainal NZ, Booth S, Huppert FA (2012) The efficacy of mindfulness-based stress reduction on mental health of breast cancer patients: a meta-analysis. Psychooncology. doi:10.1002/pon.3171 Google Scholar
  44. 44.
    Cramer H, Lauche R, Paul A, Dobos G (2012) Mindfulness-based stress reduction for breast cancer-a systematic review and meta-analysis. Curr Oncol 19:343–352. doi:10.3747/co.19.1016 CrossRefGoogle Scholar
  45. 45.
    Piet J, Würtzen H, Zacharia R (2012) The effect of mindfulness-based therapy on symptoms of anxiety and depression in adult cancer patients and suvivors: a systematic review and meta-analysis. J Consult Clin Psychol 80:1007–10020. doi:10.1037/a0028329 PubMedCrossRefGoogle Scholar
  46. 46.
    Lengacher CA, Johnson-Mallard V, Post-White J, Moscoso MS, Jacobsen PB, Klein TW, Widen RH, Fitzgerald SG, Shelton MM, Barta M, Goodman M, Cox CE, Kip KE (2009) Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. Psychooncology 18:1261–1272. doi:10.1002/pon.1529 PubMedCrossRefGoogle Scholar
  47. 47.
    Henderson VP, Clemow L, Massion AO, Hurley TG, Druker S, Hébert JR (2012) The effects of mindfulness-based stress reduction on psychosocial outcomes and quality of life in early-stage breast cancer patients: a randomized trial. Breast Cancer Res Treat 131:99–109. doi:10.1007/s10549-011-1738-1 PubMedCrossRefGoogle Scholar
  48. 48.
    Würtzen H, Dalton SO, Elsass P, Sumbundu AD, Steding-Jensen M, Karlsen RV, Andersen KK, Flyger HL, Pedersen AE, Johansen C (2013) Mindfulness significantly reduces self-reported levels of anxiety and depression: results of a randomised controlled trial among 336 Danish women treated for stage I–III breast cancer. Eur J Cancer 49:1365–1373. doi:10.1016/j.ejca.2012.10.030 PubMedCrossRefGoogle Scholar
  49. 49.
    Hoffman CJ, Ersser SJ, Hopkinson JB, Nicholla PG, Harrington JE, Thomas PW (2012) Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial. J Clin Oncol 30:1335–1342. doi:10.1200/JCO.2010.34.033.1 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Lærke Toftegård Andersen
    • 1
  • Melissa Voigt Hansen
    • 1
  • Jacob Rosenberg
    • 1
  • Ismail Gögenur
    • 1
  1. 1.Department of Surgery, Herlev HospitalUniversity of CopenhagenHerlevDenmark

Personalised recommendations